PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
July 8, 2017Neurology52 citations

Mortality trends for multiple sclerosis patients in Sweden from 1968 to 2012

View Full Paper
SBSarah BurkillSMScott MontgomeryMHMohammadhossein Hajiebrahimi

Key Points

Key points are not available for this paper at this time.

Abstract

OBJECTIVE: To assess trends in mortality and causes of death for patients with multiple sclerosis (MS) relative to those without MS in Sweden. METHODS: Patients with an MS diagnosis in Sweden between 1964 and 2012 were identified with the Patient Register and the Multiple Sclerosis Register. For this cohort study, each patient with MS (n = 29,617) was matched with 10 individuals without MS (n = 296,164) on sex, year of birth, vital status, and region of residence at the time of MS diagnosis with the Total Population Register. The Causes of Death Register was used to identify causes of death. Cox proportional hazard models were constructed to assess whether risk of mortality was increased for patients with MS. RESULTS: The hazard ratio (HR) for patients with MS was 2.92 (95% confidence interval CI 2.86-2.99) for all-cause mortality over the entire study period. The largest differences between the cohorts were death resulting from respiratory (HR 5.07, 95% CI 4.87-5.26) and infectious (HR 4.07, 95% CI 3.70-4.47) diseases. Overall and for each specific cause, there have been improvements for the MS group and a subsequent reduction in the HR. The HR decreased from 6.52 (95% CI 5.79-7.34) for the period of 1968 to 1980 to 2.08 (95% CI 1.95-2.22) for the time period of 2001 to 2012. An interaction between time period and MS exposure showed that the decrease in mortality over time was statistically significant, with a larger decrease for patients with MS than their matched comparators. CONCLUSIONS: There has been a substantial improvement in mortality overall and for each specified cause of death for patients with MS compared with individuals without MS; however, large differences still remain.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Burkill et al. (2017) studied this question.

synapsesocial.com/papers/6a635884809dd4a9e2c1d3b5https://doi.org/10.1212/wnl.0000000000004216
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study2012 · 44 citations
  2. 2MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process2015 · 424 citations
  3. 3Multiple sclerosis2004 · 315 citations
  4. 4Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study2014 · 398 citations
  5. 5A changing treatment landscape for multiple sclerosis: challenges and opportunities2014 · 59 citations